Lonza's core profits rose 9.5% to $720.6m in H1

Its pharma biotech & nutrition segment recorded 10.8% sales growth.

Swiss biotech and pharma company Lonza saw profits climb 9.5% YoY to $720.6m (CHF520m) in H1 2019 from $658.2m (CHF475m) in 2018, an SGX filing revealed.

Its total sales went up 6.4% YoY to $4.12b (CHF2.98b) from $3.87b (CHF2.8b) in H1 2018 whilst its EBITDA rose 7.7% YoY to $1.15b (CHF828m) on the back of positive performance from its pharma biotech & nutrition segment, which reported 10.8% YoY sales growth to $2.89b (CHF2.09b).

Earnings per share edged up $9.70 (CHF7) from $8.81 (CHF6.36) in H1 2018.

On the other hand, Lonza’s specialty ingredients segment sales dipped 3.8% YoY to $1.19b (CHF859m) from $1.24b (CHF893m) in H1 2018, no thanks to the decline in sales of its microbial-control and wood protection businesses.

Lonza noted that they are expecting a recovery of the said segment’s sales in H2.

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia